Phio Pharmaceuticals to present at Life Sciences Investor Forum June 24-25

Phio Pharmaceuticals will take part in the Life Sciences Investor Forum on June 24-25, 2026, with CEO Robert Bitterman set to present and hold one-on-one meetings. The event gives investors a live look at Phio’s INTASYL platform and lead candidate PH-762, a program aimed at skin cancers.

Why it matters: - Phio Pharmaceuticals is using the forum to pitch its INTASYL® siRNA platform to investors, advisors and analysts. - The presentation could help draw attention to PH-762, Phio’s lead clinical candidate for cutaneous carcinomas. - The event gives attendees a direct way to question management and schedule one-on-one meetings.

What happened: - Phio Pharmaceuticals Corp. announced that CEO and Chairman Robert Bitterman will present at the Life Sciences Investor Forum on June 25, 2026, at 3 p.m. EDT. - Bitterman will also be available for one-on-one meetings on June 24-25, 2026. - The forum will be a live, interactive online event. - The company invited investors, advisors and analysts interested in Phio Pharmaceuticals to attend. - The company posted a registration link for the event: Register here.

The details: - Bitterman will give an overview of Phio’s INTASYL® siRNA platform. - The presentation will include PH-762, the company’s lead clinical candidate for the treatment of cutaneous carcinomas. - The session will end with a live question-and-answer period. - Investors and industry professionals will be able to submit questions to management in real time. - A replay of the webcast will be available after the conference ends. - Phio recommends online investors pre-register and run the system check to speed participation and receive event updates. - Phio is a B2i Digital Featured Company. - More information about the event is available at Virtual Investor Conferences. - More information about Phio is available at the company’s website.

Between the lines: - Phio is trying to frame INTASYL as a differentiated immuno-oncology approach, according to Bitterman. - The investor forum gives Phio a platform to explain how PH-762 fits into the company’s skin cancer strategy. - The company is also signaling an emphasis on direct investor access through live Q&A and private meetings.

What's next: - Phio’s presentation and Q&A are scheduled for June 25, 2026. - One-on-one meetings run June 24-25, 2026. - The webcast replay will be posted after the conference. - Investors can pre-register ahead of the event to streamline access and receive updates.

The bottom line: - Phio is using the investor forum to spotlight its lead cancer program and test investor interest in its INTASYL platform ahead of the live presentation.